IPO News Archive
Biotech company BioHeart prices at midpoint of revised range

2/19/08


Bioheart, a biotechnology company focused on using cells derived from a patient's body for treatment of heart damage, priced its 1.1 million share offering at $5.25 on Tuesday, the midpoint of the revised range. The company had originally filed for an offering of 3.6 million shares at a range of $14-$16. The shares began trading on the NASDAQ on Tuesday under the ticker BHRT. Dawson James Securities was the sole underwriter on the deal.

View IPO Profile: BHRT         
Source: www.RenaissanceCapital.com
Latest User Comments

Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the IPO Plus Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in the IPO Plus Fund
About Fund Prospectus Invest